SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 41.22 USD 4.65% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
SpringWorks Therapeutics Inc?
Write Note

SpringWorks Therapeutics Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SpringWorks Therapeutics Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Accrued Liabilities
$66.6m
CAGR 3-Years
60%
CAGR 5-Years
91%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$14.6B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$3.2B
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.5B
CAGR 3-Years
7%
CAGR 5-Years
25%
CAGR 10-Years
24%
No Stocks Found

SpringWorks Therapeutics Inc
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 176 full-time employees. The company went IPO on 2019-09-13. The firm is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.

SWTX Intrinsic Value
42.1 USD
Undervaluation 2%
Intrinsic Value
Price

See Also

What is SpringWorks Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
66.6m USD

Based on the financial report for Dec 31, 2023, SpringWorks Therapeutics Inc's Accrued Liabilities amounts to 66.6m USD.

What is SpringWorks Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
91%

Over the last year, the Accrued Liabilities growth was 68%. The average annual Accrued Liabilities growth rates for SpringWorks Therapeutics Inc have been 60% over the past three years , 91% over the past five years .

Back to Top